Database Query Results : Photodynamic Therapy, ,

PDT, Photodynamic Therapy: Click to Expand ⟱
Features: Therapy
Photodynamic therapy is a form of phototherapy involving light and a photosensitizing chemical substance used in conjunction with molecular oxygen to elicit cell death.
Photodynamic therapy (PDT) is a 3-component cytotoxic platform: photosensitizer + light (matched wavelength) + oxygen. Light excites the photosensitizer, which then generates reactive oxygen species (ROS)—often dominated by singlet oxygen (¹O₂)—causing localized oxidative damage to tumor cells, tumor vasculature, and sometimes triggering immunogenic cell death (ICD).
Key constraints are light penetration depth and tumor hypoxia (and PDT itself can transiently consume oxygen).


Photodynamic Therapy (PDT) — Cancer-Oriented Time-Scale Flagged Pathway Table
Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Type II photochemistry: singlet oxygen (¹O₂) generation ¹O₂ ↑↑ locally; oxidative damage ↑ Localized injury only where PS+light overlap P Core cytotoxic mechanism PDT typically relies heavily on Type II energy transfer producing singlet oxygen as a primary cytotoxic agent (oxygen-dependent).
2 Type I photochemistry: radical ROS (O2•−, •OH, etc.) Radical ROS ↑ (context; PS-dependent) Localized oxidative injury (exposure-limited) P ROS amplification Type I electron-transfer pathways can contribute, especially for some PS designs and oxygen-limited niches.
3 Direct tumor cell kill (membrane/protein/DNA oxidation) Apoptosis/necrosis/other death programs ↑ (context) Collateral damage limited by targeting + light field R, G Local tumor cytotoxicity Oxidative injury can trigger multiple death modes; outcome depends on dose, PS localization (membrane/mitochondria/lysosome), and oxygen.
4 Vascular shutdown (tumor vasculature damage) Perfusion ↓; secondary hypoxia/ischemia ↑ Local vascular injury possible R Indirect tumor starvation PDT can damage tumor-associated vessels, restricting nutrient/oxygen supply and contributing to delayed tumor kill.
5 Oxygen dependence / hypoxia limitation Efficacy ↓ in hypoxic tumors; PDT consumes O2 during reaction — P, R Core constraint Tumor hypoxia is a major barrier; PDT can transiently reduce local oxygen levels during illumination.
6 Immune activation / immunogenic cell death (ICD) DAMP release ↑; anti-tumor immunity ↑ (protocol/PS-dependent) Inflammatory signaling ↑ locally G Systemic immune leverage PDT can trigger ICD and stimulate adaptive immune responses, but this is highly dependent on photosensitizer and protocol.
7 Inflammation & cytokine wave (acute) Local cytokines ↑; immune cell recruitment ↑ Local inflammation ↑ R, G Microenvironment remodeling Post-PDT inflammation can support tumor clearance or, if suboptimal, contribute to repair/regrowth; protocol matters.
8 Combination leverage (radiation/chemo/immunotherapy) Sensitization ↑ (context-dependent) — G Adjunct synergy PDT is often paired with other modalities; strongest logic is local tumor kill + immune priming + improved control of residual disease.
9 Light penetration depth constraint Deep tumors harder to treat (limited light reach) — — Translation constraint Most activation light has limited tissue penetration; strategies include fiber optics, endoscopic delivery, or NIR-shifted PS designs.
10 Photosensitizer PK & phototoxicity risk PS accumulation affects selectivity Skin/eye photosensitivity risk (agent-dependent) R, G Clinical constraint Systemic photosensitizers can cause prolonged photosensitivity; topical/ALA-based approaches reduce systemic exposure in some uses.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (photoactivation + ROS burst)
  • R: 30 min–3 hr (vascular effects, acute stress signaling)
  • G: >3 hr (cell-death completion, immune recruitment, ICD outcomes)


Common Clinical Photosensitizers for Cancer PDT
Photosensitizer Class Activation Wavelength (nm) Penetration Depth* Photosensitivity Duration Typical Clinical Use Notes
5-ALA (→ Protoporphyrin IX) Endogenous porphyrin precursor ~630–635 nm Shallow–Moderate (~2–5 mm) Short (24–48 hrs; topical shorter) Skin cancers, actinic keratosis, bladder, glioma visualization Prodrug converted intracellularly to PpIX; good tumor selectivity; minimal prolonged systemic photosensitivity.
Porfimer sodium (Photofrin®) First-generation porphyrin ~630 nm Moderate (~5–10 mm) Long (4–6 weeks) Esophageal, lung, bladder cancers Prolonged skin photosensitivity is a major limitation.
Temoporfin (Foscan®) Chlorin ~652 nm Moderate (~5–10 mm) 2–3 weeks Head & neck cancers Higher potency than Photofrin; improved absorption spectrum.
Verteporfin (Visudyne®) Benzoporphyrin derivative ~689 nm Moderate–Deeper (~5–10+ mm) Short (few days) Primarily ophthalmology; investigated in oncology Better red/NIR absorption; shorter photosensitivity window.
Talcaporfin sodium (Laserphyrin®) Chlorin derivative ~664 nm Moderate (~5–10 mm) Short (~1–2 weeks) Lung, brain tumors (Japan) Improved safety vs first-generation porphyrins.
Methylene Blue Phenothiazine dye ~660–670 nm Shallow–Moderate Short Experimental oncology; antimicrobial PDT Strong Type I ROS contribution; also has redox cycling effects without light.
Hypericin Natural anthraquinone ~590–600 nm Shallow Variable Investigational High singlet oxygen yield; hydrophobic; not widely used clinically.

*Penetration depth depends on wavelength, tissue optical properties, and light delivery method. Red/NIR light (~650–700 nm) penetrates deeper than blue/green light.



Scientific Papers found: Click to Expand⟱
5270- 5-ALA,  PDT,    5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy
- Review, Var, NA
"highlight2" >other↝, "highlight2" >ROS↑, "highlight2" >other↝, "highlight2" >mtDam↑, "highlight2" >Ca+2↑, "highlight2" >ER Stress↑, "highlight2" >Apoptosis↑, "highlight2" >TumAuto↑, "highlight2" >other↝, "highlight2" >Dose↝, "highlight2" >Imm↑,
336- AgNPs,  PDT,    Photodynamic ability of silver nanoparticles in inducing cytotoxic effects in breast and lung cancer cell lines
- in-vitro, BC, MCF-7
"highlight2" >Apoptosis↑,
4564- AgNPs,  GoldNP,  Cu,  Chemo,  PDT  Cytotoxicity and targeted drug delivery of green synthesized metallic nanoparticles against oral Cancer: A review
- Review, Var, NA
"highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >TumCCA↑, "highlight2" >eff↑, "highlight2" >Apoptosis↑, "highlight2" >eff↓, "highlight2" >ChemoSen↑,
335- AgNPs,  PDT,    Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy
- Review, NA, NA
"highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >GPx↑, "highlight2" >Catalase↓, "highlight2" >SOD↓, "highlight2" >p38↑, "highlight2" >BAX↑, "highlight2" >Bcl-2↓,
1374- BBR,  PDT,    Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells
- in-vitro, RCC, 786-O - in-vitro, RCC, HK-2
"highlight2" >ROS↑, "highlight2" >TumAuto↑, "highlight2" >Apoptosis↑, "highlight2" >Casp3↑, "highlight2" >eff↑,
2680- BBR,  PDT,    Photodynamic therapy-triggered nuclear translocation of berberine from mitochondria leads to liver cancer cell death
- in-vitro, Liver, HUH7
"highlight2" >TumCD↑, "highlight2" >ROS↑, "highlight2" >TumCCA↑, "highlight2" >ER Stress↑,
2681- BBR,  PDT,    Berberine-photodynamic induced apoptosis by activating endoplasmic reticulum stress-autophagy pathway involving CHOP in human malignant melanoma cells
- in-vitro, Melanoma, NA
"highlight2" >Apoptosis↑, "highlight2" >cl‑Casp3↑, "highlight2" >LC3s↑, "highlight2" >ER Stress↑, "highlight2" >ROS↑, "highlight2" >CHOP↑,
483- CUR,  PDT,    Visible light and/or UVA offer a strong amplification of the anti-tumor effect of curcumin
- in-vivo, NA, A431
"highlight2" >TumVol↓, "highlight2" >TumCP↓, "highlight2" >Apoptosis↑,
484- CUR,  PDT,    Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light
- in-vitro, Melanoma, NA
"highlight2" >Cyt‑c↑, "highlight2" >Casp9↑, "highlight2" >Casp8↑, "highlight2" >NF-kB↓, "highlight2" >EGFR↓,
485- CUR,  PDT,    Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin
- in-vitro, Melanoma, NA
"highlight2" >NF-kB↓, "highlight2" >Casp8↑, "highlight2" >Casp9↑, "highlight2" >p‑Akt↓, "highlight2" >p‑ERK↓,
482- CUR,  PDT,    The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro
- in-vitro, Bladder, RT112 - in-vitro, Bladder, UMUC3
"highlight2" >Apoptosis↑, "highlight2" >TumCG↓, "highlight2" >TumCP↓,
1175- IVM,  PDT,    Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors
- in-vitro, Var, NA
"highlight2" >Hypoxia↓, "highlight2" >mitResp↓, "highlight2" >ROS↑,
2532- M-Blu,  PDT,    Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies
- Review, Var, NA
"highlight2" >AntiCan↑,
2533- M-Blu,  PDT,    Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells
- in-vitro, Lung, A549
"highlight2" >MMP↓, "highlight2" >p‑MAPK↑, "highlight2" >ROS↑, "highlight2" >cl‑PARP↑, "highlight2" >Bcl-2↓, "highlight2" >Mcl-1↓, "highlight2" >eff↓,
2534- M-Blu,  doxoR,  PDT,    Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells
- in-vitro, CRC, HT-29
"highlight2" >LDH↑, "highlight2" >ROS↑,
1476- SFN,  PDT,    Enhancement of cytotoxic effect on human head and neck cancer cells by combination of photodynamic therapy and sulforaphane
- in-vitro, HNSCC, NA
"highlight2" >eff↑, "highlight2" >tumCV↓, "highlight2" >ROS↑, "highlight2" >eff↓, "highlight2" >Casp↑,
1834- VitK3,  PDT,    Effects of Vitamin K3 Combined with UVB on the Proliferation and Apoptosis of Cutaneous Squamous Cell Carcinoma A431 Cells
- in-vitro, Melanoma, A431
"highlight2" >eff↑, "highlight2" >TumCG↓, "highlight2" >TumCP↓, "highlight2" >ROS↑, "highlight2" >MMP↓,
1838- VitK3,  PDT,    Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways
- in-vitro, Cerv, NA
"highlight2" >eff↑, "highlight2" >ROS↑, "highlight2" >tumCV↓, "highlight2" >TumCG↓, "highlight2" >Apoptosis↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp9↑, "highlight2" >Bcl-xL↑, "highlight2" >Cyt‑c↑, "highlight2" >Bcl-2↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 18

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   GPx↑, 1,   GSH↓, 1,   ROS↑, 12,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

mitResp↓, 1,   MMP↓, 2,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

LDH↑, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↑, 8,   BAX↑, 1,   Bcl-2↓, 3,   Bcl-xL↑, 1,   Casp↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 2,   Casp8↑, 2,   Casp9↑, 2,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   p‑MAPK↑, 1,   Mcl-1↓, 1,   p38↑, 1,   TumCD↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 3,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 3,  

Autophagy & Lysosomes ⓘ

LC3s↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,   TumCG↓, 3,  

Migration ⓘ

Ca+2↑, 1,   TumCP↓, 3,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   Hypoxia↓, 1,  

Immune & Inflammatory Signaling ⓘ

Imm↑, 1,   NF-kB↓, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,   eff↓, 3,   eff↑, 5,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   LDH↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   TumVol↓, 1,  
Total Targets: 50

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:175  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page